Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic
- Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors
- Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up
- To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers
Oxford, UK – 20 March 2025 – Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1, to treat patients with oesophageal cancer.
